Voxzogo 1.2mg Kit
Product Images NDC 68135-181

Product Visual Gallery

This gallery contains 37 technical images submitted to the FDA as part of the official labeling for Voxzogo 1.2mg (NDC 68135-181). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Biomarin Pharmaceutical Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Voxzogo 01)

Chemical structure diagram of vosoritide, the active ingredient in VOXZOGO 0.56mg. The structure shows the arrangement of atoms and bonds in the vosoritide molecule, a peptide compound used in this prescription drug kit by BioMarin Pharmaceutical Inc.*

FDA Label Image

Image (Voxzogo 02)

An instructional diagram showing the components of a vial cap. It highlights the vial stopper underneath the cap and indicates the position of the medicine powder inside the vial. Labels point to the cap, vial, and medicine powder, providing a clear visual explanation of the vial's sealing and contents.*

FDA Label Image

Image (Voxzogo 03)

VOXZOGO 0.56mg alcohol pad packaging label showing a white sachet with text 'ALCOHOL PAD' in simple black font. The sachet is square-shaped and appears as a single-use wipe packet. No other branding or detailed information is visible on the packaging.*

FDA Label Image

Image (Voxzogo 04)

An instructional diagram illustrating a diluent needle labeled with its components: safety shield, blue tab to retract needle, and needle cap with the needle inside, providing guidance on needle usage.*

FDA Label Image

Image (Voxzogo 05)

Illustration of a red sharps container labeled "SHARPS" in white text with a white handle, used for disposal of medical needles and sharp instruments.*

FDA Label Image

Image (Voxzogo 06)

An instructional illustration showing a prefilled diluent syringe labeled with parts including the cap, diluent, and plunger rod. The syringe contains sterile water for reconstitution of BMN-111, corresponding to Voxzogo 0.56mg kit by BioMarin Pharmaceutical Inc.*

FDA Label Image

Image (Voxzogo 07)

An instructional illustration showing a gauze pad and adhesive bandage overlapping, labeled 'Gauze or Bandage.'*

FDA Label Image

Image (Voxzogo 08)

An instructional illustration showing the parts of an injection syringe used with VOXZOGO 0.56mg (vosoritide) kit. The diagram labels the needle cap covering the needle, the syringe barrel with measurement markings, and the plunger rod used to administer the injection.*

FDA Label Image

Step 1 (Voxzogo 09)

An instructional illustration showing how to remove the vial stopper by lifting the flip cap and a hand pushing the stopper down. The image includes a warning: do not touch the vial stopper with your fingers after wiping it with an alcohol pad.*

FDA Label Image

Step 2 (Voxzogo 10)

An instructional illustration showing hands assembling a syringe by attaching the needle cap to the syringe body, likely demonstrating proper preparation for injection. This relates to the VOXZOGO 0.56mg (vosoritide) kit for human prescription use by BioMarin Pharmaceutical Inc.*

FDA Label Image

Step 3 (Voxzogo 11)

An instructional illustration showing a person holding a syringe and a vial. The image depicts the action of attaching or mixing a component from the vial to the syringe, indicated by blue arrows and wavy lines representing the transfer or mixing process. This diagram is likely part of the preparation instructions for the VOXZOGO 0.56mg kit.*

FDA Label Image

Step 4 (Voxzogo 12)

An instructional diagram depicting the preparation steps for a syringe kit. It shows hands manipulating a syringe with emphasis on not pushing the blue tab until a specified step, indicating careful assembly or use of components.*

FDA Label Image

Step 5 (Voxzogo 13)

An instructional illustration showing the steps to retract the needle of a syringe. The first step shows a hand pulling up the blue needle cap with a caution to avoid touching the needle tip. The second step demonstrates pressing the blue tab to retract the needle back into the syringe.*

FDA Label Image

Step 6 (Voxzogo 14)

An instructional illustration showing a hand holding a vial while rotating it to mix the contents. The caption advises ensuring the medicine is clear to yellow, not cloudy, and contains no hard particles before use.*

FDA Label Image

Step 7 (Voxzogo 15)

Illustrative instructions for preparing a VOXZOGO 0.56mg kit injection. The first panel shows removing the syringe from the package, the second advises not to place the cap back on the needle after removal, and the third warns to avoid bending the needle when inserting it into a vial or rubber stopper.*

FDA Label Image

Step 8 (Voxzogo 16)

An instructional illustration showing how to hold a vial and syringe during preparation. It emphasizes that the vial should be positioned on top and cautions to avoid bending the needle while attaching the vial to the syringe. The hand positions are clearly depicted for proper handling.*

FDA Label Image

Step 9 (Voxzogo 17)

Instructional illustration showing a hand drawing up a prescribed dose with a syringe. The syringe is held upright, and an arrow indicates the direction to draw the medication.*

FDA Label Image

Step 10 (Voxzogo 18)

An instructional diagram illustrating proper use of a syringe or vial device. The illustration shows a hand tapping the bubbles up within the syringe and another hand slowly pushing the bubbles out, demonstrating steps to remove air bubbles from the dosage form.*

FDA Label Image

Step 11 (Voxzogo 19)

An instructional illustration showing a syringe filled with liquid, labeled to indicate acceptable bubble size and volume markings from 0.1 to 0.4 mL. It instructs removing large bubbles and ensuring the syringe dose matches the prescribed amount, emphasizing 1 or 2 small bubbles are acceptable. The image focuses on guidance for measuring and removing bubbles before injection.*

FDA Label Image

Step 12 (Voxzogo 20)

An instructional illustration showing two hands preparing a syringe. One hand holds a syringe attached to a vial, while the other hand pulls the syringe plunger upward. Text advises to ensure the dose in the syringe matches the prescribed dose before removing the vial.*

FDA Label Image

Step 13 (Voxzogo 21)

An instructional diagram showing recommended injection sites for VOXZOGO 0.56mg kit. It advises avoiding injection through clothes or into damaged skin. The highlighted injection sites include the thighs, abdomen (2 inches from belly button), buttocks, and the back of the upper arms, illustrated on front and back body outlines.*

FDA Label Image

Step 14 (Voxzogo 22)

An instructional illustration associated with VOXZOGO 0.56mg kit showing a hand lifting a flap or adhesive strip with a caution symbol and text advising not to touch the area again before injecting. The image emphasizes careful preparation prior to injection.*

FDA Label Image

Step 15 (Voxzogo 23)

An instructional illustration showing a hand administering an injection with a syringe into the skin, demonstrating the technique for subcutaneous injection.*

FDA Label Image

Step 16 (Voxzogo 24)

An instructional illustration showing a hand holding a syringe at a 45-degree angle for an injection into a forearm. The diagram emphasizes the correct injection angle with a bold arrow and a labeled 45° angle.*

FDA Label Image

Step 17 (Voxzogo 25)

An instructional illustration showing how to use a prefilled syringe for injection. It depicts a hand with a finger pressing down on the syringe plunger to inject the full dose, emphasizing correct technique for delivering the medication dose.*

FDA Label Image

Step 17 (Voxzogo 26)

Instructional illustration showing how to use a syringe by pressing on the plunger. The image indicates that continued pressing will cause the needle to retract, enhancing safety during injection. This diagram provides visual guidance on the injection procedure.*

FDA Label Image

Image (Voxzogo 27)

VOXZOGO 0.56 mg kit packaging label by BioMarin Pharmaceutical Inc. The label includes the proprietary name VOXZOGO, the strength 0.56 mg, and the form identified as a kit. This is a human prescription drug containing the active ingredient vosoritide.*

FDA Label Image

Step 18 (Voxzogo 28)

An instructional illustration showing a needle and syringe being disposed into a sharps container labeled "SHARPS" in white text on a red background. A black arrow points downward indicating the proper disposal direction into the container.*

FDA Label Image

Principal Display Panel (Kit Carton)

Packaging label for VOXZOGO 0.4 mg per vial (vosoritide) for injection, a human prescription drug kit by BioMarin Pharmaceutical Inc. The label indicates the kit is for subcutaneous use only and must be reconstituted with the provided diluent. The carton contains ten single-dose vials, disposable prefilled syringes with diluent, sterile needles, and patient information. Storage instructions specify refrigeration with protection from light.*

FDA Label Image

Principal Display Panel (0.4 mg Vial Label)

Label for VOXZOGO (vosoritide) for injection 0.4 mg per vial. The label indicates the product is a single-dose vial for subcutaneous use only, to be reconstituted prior to use. The label includes the manufacturer BioMarin and denotes prescription use only (Rx Only).*

FDA Label Image

Principal Display Panel (0.5 mL Syringe Label)

Label for VOXZOGO 0.56mg diluent for injection, indicating a single-dose vial with 0.5 mL volume. The label includes instructions to use as a drug diluent and reconstitute as directed. Distributed by BioMarin Pharmaceutical Inc., the label also includes the NDC 68135-070-12 and notes it contains no preservative.*

FDA Label Image

Principal Display Panel (Kit Carton)

The image shows the flat packaging label for VOXZOGO 0.56 mg kit, a human prescription drug containing vosoritide for injection. The label features the product name VOXZOGO prominently with the strength 0.56 mg per vial and states it is for subcutaneous use only. The manufacturer BioMarin Pharmaceutical Inc. is noted. The carton contents and storage instructions are detailed, including ten single-dose vials, syringes, and reconstitution info. The label includes NDC 68135-119-66 and barcodes.*

FDA Label Image

Principal Display Panel (0.56 mg Vial Label)

Label for VOXZOGO 0.56 mg per vial (vosoritide) for injection kit by BioMarin Pharmaceutical Inc. Indicates the product is for subcutaneous use, single-dose vial, and Rx only. Includes barcode and spaces for lot and expiration information.*

FDA Label Image

Principal Display Panel (0.7 mL Syringe Label)

Label for a diluent vial used with VOXZOGO for Injection showing 0.7 mL volume. The label states it is for drug diluent use only, single-dose, no preservative, and distributed by BioMarin Pharmaceutical Inc. It includes an NDC code 68135-102-43 and space for lot and expiration dates.*

FDA Label Image

Principal Display Panel (Kit Carton)

Packaging label for VOXZOGO 1.2 mg per vial (vosoritide) for injection, a human prescription drug by BioMarin Pharmaceutical Inc. The label specifies the product is for subcutaneous use only and must be reconstituted with diluent provided. The carton contains ten single-dose vials, disposable syringes, needles, and prescribing information. Storage and usage instructions are included.*

FDA Label Image

Principal Display Panel (1.2 mg Vial Label)

Label for VOXZOGO (vosoritide) for injection, showing a single-dose vial with a strength of 1.2 mg per vial. The label includes instructions to reconstitute prior to use and indicates subcutaneous use only. The manufacturer is BioMarin Pharmaceutical, with space for lot number and expiration date.*

FDA Label Image

Principal Display Panel (0.6 mL Syringe Label)

Label for VOXZOGO Diluents for Injection, showing a 0.6 mL single-dose vial. It is marked for Rx only, preservative-free, and distributed by BioMarin Pharmaceutical Inc. The label includes the NDC number 68135-158-17 and notes use for drug diluent only, to reconstitute as directed.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.